Singapore's Health Sciences Authority (HSA) has approved QINLOCK® (ripretinib) for the treatment of patients with 4th line GIST QINLOCK significantly reduced the risk of disease progression or death by 85% and showed clinically meaningful overall survival in the INVICTUS Phase 3 Study1,2 SINGAPORE, May 8, 2023 /PRNewswire/ -- Independent biopharmaceutical company Specialised Therapeutics Asia (ST) is pleased to...